NETRIS Pharma

Description

NETRIS Pharma develops therapeutics that target Netrin-1 to overcome resistance to oncology treatments, producing monoclonal antibodies (e.g., NP137) for use in chemotherapy, targeted therapy and immunotherapy-resistant solid tumors.

Related

• RS ResearchRS Research develops targeted oncology therapies and smart nanomedicines using the Sagitta® polymer-drug conjugate platform for targeted…
• ThelperThelper develops antiviral antibody–drug conjugates that target a virally encoded biomarker abundantly expressed in aggressive, metastatic…
• Molecular PartnersMolecular Partners develops DARPin therapeutics, including Radio-DARPins and logic-gated Switch-DARPins, to target DLL3, FAP x CD40, and…
• OncomatryxOncomatryx targets the tumor microenvironment with stroma-focused antibody-drug conjugates, applying this approach to metastatic solid…
• Betaglue® TherapeuticsBetaglue® Therapeutics develops localized radiotherapeutic platforms delivering radiation directly into solid tumors, producing precision…
• Hansa BiopharmaHansa Biopharma develops immunomodulating antibody-cleaving enzyme therapies that target and inactivate IgG antibodies, inhibiting…
• Tessellate BioTessellate Bio discovers and develops precision oncology small-molecule medicines based on novel synthetic lethality interactions,…
• Oy Medix BiochemicaOy Medix Biochemica supplies diagnostic raw materials, including monoclonal and polyclonal antibodies, native and recombinant antigens,…
• CytovationCytovation develops CyPep-1, a tumor membrane-targeted immunotherapy, using peptide engineering to activate immune recognition and tumor…